Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.5%

2 terminated out of 21 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed with results

Key Signals

83% success

Data Visualizations

Phase Distribution

6Total
Not Applicable (5)
P 2 (1)

Trial Status

Completed10
Unknown5
Terminated2
Recruiting2
Enrolling By Invitation1
Active Not Recruiting1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT07059624Not ApplicableRecruiting

Femoral Arterial Cannulation in Pediatrics

NCT06583200Not ApplicableEnrolling By InvitationPrimary

Fluid Responsiveness in Post Cardiac Surgery Patients

NCT05762601RecruitingPrimary

Cellular precOnditioning for Post-Surgical Myocardial Ischemic Complications - Observational Study

NCT03892226Active Not Recruiting

Cardiomyocyte Injury Following Acute Ischemic Stroke

NCT04063397Completed

Persistent Postpartum Cardiovascular Dysfunction in Patients With Preeclampsia

NCT03209674Unknown

Registry for the Improvement of Postoperative OutcomeS in Cardiac and Thoracic surgEry

NCT05569798Not ApplicableUnknown

The INSIGHT Feasibility Study Ultrasound in the Intensive Care Unit: A Randomised Controlled Feasibility Trial

NCT04435457Terminated

Cardiovascular Implications of COVID-19

NCT04753762Completed

Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection

NCT03882580Unknown

Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care

NCT05770336CompletedPrimary

STUDIO DELLE MANIFESTAZIONI CARDIOVASCOLARI A LUNGO TERMINE MEDIANTE TECNICHE DI IMAGING

NCT05602298Unknown

The Quality of Recovery-15 Survey After Cardiac Surgery

NCT04501822Completed

One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia

NCT05114408Not ApplicableUnknownPrimary

Trimodal Prehabilitation in Patients Undergoing Elective Surgery

NCT04433546Phase 2Terminated

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04013360Not ApplicableCompleted

Acute Effect of Positive Expiratory Pressure Versus Breath Stacking Technique After Cardiac Surgery

NCT03387540Completed

Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions

NCT03413176CompletedPrimary

Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.

NCT03566368Completed

Cardiac Dysfunction in Traumatic Brain Injury

NCT03188341Completed

Cardiac Complication After Vascular Surgery

Scroll to load more

Research Network

Activity Timeline